Johns Hopkins HIV Guide
Letermovir
INDICATIONS
FDA
FDA
- Prophylaxis of cytomegalovirus infection (CMV) in adult and pediatric patients (6 months of age and older and weighing at least 6 kg) who are CMV-seropositive [R+] recipients of an allogeneic hematopoietic stem cell transplant
- Prophylaxis of CMV in adult and pediatric patients (12 years of age and older and weighing at least 40 kg) who are kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-])
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 12, 2025
Citation
Soto, Caitlin . "Letermovir." Johns Hopkins HIV Guide, The Johns Hopkins University, 2025. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir.
Soto C. Letermovir. Johns Hopkins HIV Guide. The Johns Hopkins University; 2025. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir. Accessed October 8, 2025.
Soto, C. (2025). Letermovir. In Johns Hopkins HIV Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir
Soto C. Letermovir [Internet]. In: Johns Hopkins HIV Guide. The Johns Hopkins University; 2025. [cited 2025 October 08]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Letermovir
ID - 545271
A1 - Soto,Caitlin ,PharmD, BCIDP
Y1 - 2025/06/12/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
